|
 |
Technologies & Capabilities
S*BIO’s target-driven approach to innovative small molecule therapies for cancer is built on a profound understanding of cancer biology and our ability to translate that understanding into best-in-class clinical compounds. Our state-of-the-art infrastructure includes a comprehensive technology platform covering the drug discovery value chain, from target identification and validation to profiling of pre-clinical development candidates.
With access to over a quarter of a million drug like molecules plus the latest high throughput screening technology, we are able to identify multiple new lead candidates every year. A complementary lead finding approach is computational chemistry that is also supporting our strong team of experienced scientists and biologists in the lead optimisation phase. Rapid optimisation of promising lead compounds into first-in-class and best-in-class development candidates is one of the core competencies of S*BIO.
This is achieved by an international multi-skilled scientific team under the leadership of a highly experienced senior management.
 Back to top
Copyright © 2002-2011 S*BIO Pte Ltd. All rights reserved.
|
|
